Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

SAB2500803

Sigma-Aldrich

Anti-Plasminogen Activator/PLAU antibody produced in goat

affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-ATF, Anti-HGNC:9052, Anti-Plasminogen activator, Anti-UPA, Anti-Urokinase

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

goat

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

human

technique(s)

indirect ELISA: suitable
western blot: suitable

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... PLAU(5328)

General description

Urokinase-type plasminogen activator is also known as PLAU and uPA. The human uPA is initially synthesized as 431 amino acid precursor with an N-terminal signal peptide (20 residues). The single chain molecule is processed into a disulfide-linked two-chain molecule of different molecular weights. Two forms of the A chain exist, starting at Ser21 (the long form) and Lys156 (the short form). The long and short A chains are unique to the high and low molecular weight forms, respectively. The long A chain contains an EGF (epidermal growth factor)-like domain, responsible for binding of the PLAU receptor. The B chain corresponds to the catalytic domain. The gene encoding it is localized on human chromosome 10.

Immunogen

Peptide with sequence C-HFLPWIRSHTKEEN from the C Terminus of the protein sequence according to NP_002649.1.

Biochem/physiol Actions

Urokinase-type plasminogen activator is a serine protease with extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. It is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SAB2500803-100UG:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
Spraggon G
Structure, 3(7), 681-691 (1995)
Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22.
Yasuda S
Blood, 105(10), 3893-3901 (2005)
Identification of a novel inhibitor of urokinase-type plasminogen activator.
Zhu M
Molecular Cancer Therapeutics, 6(4), 1348-1356 (2007)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service